Orexigen® Therapeutics Presents Additional Contrave Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring

Orexigen Therapeutics, Inc.

announced additional data that showed that overweight and obese patients treated with Contrave®(naltrexone sustained release (

)/bupropion SR) maintained normal 24-hour circadian patterns over one year of treatment. These data were from the ambulatory blood pressure monitoring ub-study of the COR-II trial that also showed weight loss and improvements in markers of cardiometabolic risk. Data were presented at the 60th Annual Scientific Session of the American College of Cardiology taking place in New Orleans.